Compound

Compound. Means that certain pharmaceutical compound known as [***].

Compound. Means, with respect to each Licensed Product, the active pharmaceutical ingredient for such Licensed Product approved by CyDex in accordance with Section 2.5, owned by or exclusively licensed to Company and developed and manufactured by or on behalf of Company.

Compound. All the compounds which are selective phosphodiesterase type-5 inhibitor, which compounds are contained within a claim of any unexpired TANABE PATENT no matter when filed or in a claim of a pending application for a TANABE PATENT no matter when filed which is being prosecuted in good faith by or on behalf of TANABE or its AFFILIATE, including without limitation the compound coded as T-1790 by TANABE, chemically known as [***].

Compound. Ganaxolone (i.e., 3β-Methyl-3α-ol-5α-pregnan-20-one or 3α-Hydroxy-3β-methyl-5α-pregnan-20-one)

Compound. The amphetamine polistirex active pharmaceutical ingredient in the Neos Product of the Neos NDA as of the Effective Date

Compound. Defined in the Commercial License Agreement

Compound. Means that certain neuroactive steroid known as Allopregnanolone.

Compound. Droxidopa.

Compound. Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one), the chemical structure of which is described in Schedule 1, in any formulation, the use, Development or Commercialization of which in the absence of the TTA, a sublicense to a Permitted Transferee or other ownership, assignment or license of applicable rights, would infringe at least one Valid Claim of the Assigned IP or Company Patent Rights, or that is manufactured or otherwise produced, at least in part, using Company Know-How.

Compound. Shall mean any chemical compound that has been screened, tested or synthesized by SCYNEXIS under this Agreement and: (1) whose structure is [*], (2) the property(-ies) or activity(-ies) of which [*], or (3) that is [*] or [*] but is not [*] or [*].